Skip to main content
TipRanks
Go Ultimate75% OFF

Spyre Therapeutics (SYRE) AI Stock Analysis

586 Followers
SYRE

Spyre Therapeutics

(NASDAQ:SYRE)

Select Model
Rating:64Neutral
Price Target:$106.00â–²(1.92% Upside)
Action:reiterated
Date:11/04/26

The score is primarily held back by weak financial performance—large losses and significant cash burn despite a strong, debt-free balance sheet. Technicals are supportive with an established uptrend and positive momentum. Corporate events are net positive due to encouraging Phase 2 data and added funding, though dilution risk remains. Valuation is constrained by ongoing losses (negative P/E) and no dividend support.

Positive Factors
Diversified IBD pipelineClinical proof-of-concept across three distinct IBD mechanisms gives Spyre multiple opportunities to generate value and reduces reliance on one candidate. Advancing into randomized combination studies could support differentiated efficacy, broader treatment options, and a stronger competitive position if results remain positive.
Negative Factors
High cash burnThe company is consuming cash at a substantial rate, and outflows increased from prior annual periods. Persistent burn raises funding-duration and execution risks because Spyre must continue financing research and trials before commercial products can generate recurring cash flow.

Spyre Therapeutics (SYRE) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%250%300%350%400%SYRE+331.54%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$9.88B
Dividend Yield
―
Average Volume (3M)
1.26M
Price to Earnings (P/E)
-38.0
Beta (1Y)
1.73
Revenue Growth
―
EPS Growth
-41.56%
Country
US
Employees
125
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Spyre Therapeutics Business Overview & Revenue Model

Company Description

Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclo...

How the Company Makes Money

Spyre Therapeutics is a clinical-stage biotech company, and its ability to generate recurring product revenue depends on successfully developing and commercializing approved therapeutics. As of the latest publicly available information, the company d...

Spyre Therapeutics Financial Statement Overview

Summary

Balance sheet strength (no debt and sizable equity base) supports solvency, but operating performance is weak with large operating/net losses and high ongoing cash burn (TTM operating and free cash flow about -$249.3M). Revenue and gross margin are encouraging, yet profitability and self-funding capacity remain the key constraint.

Income Statement

22Negative

Balance Sheet

78Positive

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue90.49M00886.00K2.33M18.74M
Gross Profit45.25M-171.65M0886.00K2.33M18.74M
EBITDA-270.49M-209.56M-207.97M-127.82M-81.99M-64.08M
Net Income-263.86M-155.20M-208.02M-338.79M-83.81M-65.80M
Balance Sheet
Total Assets1.10B777.78M608.48M341.86M71.14M109.93M
Cash, Cash Equivalents and Short-Term Investments1.07B756.53M603.09M339.28M55.71M93.13M
Total Debt00004.63M5.06M
Total Liabilities48.19M62.55M90.68M157.84M20.84M25.98M
Stockholders Equity1.05B715.24M517.80M184.02M50.30M83.94M
Cash Flow
Free Cash Flow-249.32M-169.25M-157.41M-99.91M-80.18M-54.29M
Operating Cash Flow-249.32M-169.25M-157.41M-99.91M-80.14M-53.72M
Investing Cash Flow-492.54M-143.47M-353.29M-108.39M57.01M-22.62M
Financing Cash Flow759.69M309.02M410.91M361.08M42.68M1.39M

Spyre Therapeutics Technical Analysis

Technical Analysis SentimentPositive
Last Price104.00

Price Trends

50DMA91.48Positive
100DMA94.78Positive
200DMA76.67Positive

Market Momentum

MACD4.23Negative
RSI59.40Neutral
STOCH66.07Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRE, the sentiment is Positive. The current price of 104.00 is above the 20-day moving average (MA) of 98.02, above the 50-day MA of 91.48, and above the 200-day MA of 76.67, indicating a bullish trend. The MACD of 4.23 indicates Negative momentum. The RSI at 59.40 is Neutral, neither overbought nor oversold. The STOCH value of 66.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYRE.

Spyre Therapeutics Risk Analysis

Spyre Therapeutics disclosed 73 risk factors in its most recent earnings report. Spyre Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights.Q2, 2026
2.The market price of our common stock has historically been volatile, and the market price of our common stock may decline in the future.Q2, 2026
3.Anti-takeover provisions in our charter documents and under Delaware law and the terms of some of our contracts could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.Q2, 2026

Spyre Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SYRE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ORKAORKA68Neutral$7.15B-43.71-18.66%――-2.35%
SYRESYRE64Neutral$9.88B-37.96-29.82%――-41.56%
IMVTIMVT53Neutral$7.07B-13.35-63.01%――9.82%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ZBIOZBIO51Neutral$1.90B-2.79-208.91%―-26.67%-121.60%
ABVXABVX40Underperform$7.63B-16.79-85.88%―――
MLTXMLTX39Underperform$1.06B-3.40-79.95%――-10.20%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%SYREORKAIMVTMLTXABVXZBIODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SYRE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SYRESpyre Therapeutics, Inc104.0079.64326.93%
ORKAOruka Therapeutics, Inc.105.3577.12273.18%
IMVTImmunovant, Inc.34.189.8840.66%
MLTXMoonlake Immunotherapeutics12.50-0.49-3.77%
ABVXAbivax SA Sponsored ADR87.58-26.04-22.92%
ZBIOZenas BioPharma, Inc.28.01-7.87-21.93%

Spyre Therapeutics Corporate Events

Business Operations and StrategyPrivate Placements and Financing

Spyre Therapeutics Announces Major Equity Financing Agreement

Positive
Oct 7, 2026

On October 5, 2026, Spyre Therapeutics entered into an underwriting agreement with a syndicate of investment banks to offer 4,117,648 shares of common stock at $85.00 per share, with a 30-day option for underwriters to buy up to an additional 617,647...

Business Operations and StrategyProduct-Related Announcements

Spyre Therapeutics Reports Positive Phase 2 SKYLINE Data

Positive
Sep 8, 2026

On September 8, 2026, Spyre Therapeutics reported positive 12-week induction topline data from Part A of its Phase 2 SKYLINE trial, evaluating SPY003, an extended half-life anti-IL-23 antibody for moderately-to-severely active ulcerative colitis. SPY...

Business Operations and StrategyProduct-Related Announcements

Spyre Therapeutics reports Phase 2 TL1A trial results

Positive
Aug 25, 2026

On August 25, 2026, Spyre Therapeutics reported topline results from the rheumatoid arthritis sub-study of its Phase 2 SKYWAY basket trial of TL1A antibody SPY072, showing both tested doses achieved statistically significant benefits versus placebo o...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026